Nephropathy in Type 1 Diabetes

Michel Marre

doi:10.1055/s-2002-23100

Seminars in Vascular Medicine, Table of Contents

Semin Vasc Med 2002; 2(1): 097-108
DOI: 10.1055/s-2002-23100

Nephropathy in Type 1 Diabetes

Michel Marre

Service d'Endocrinologie Diabétologie Métabolisme Nutrition, Centre Hospitalier Universitaire Bichat-Claude Bernard, Paris, France

Abstract

ABSTRACT

Nephropathy is the major life-threatening complication of type 1 diabetes. It is due to the adverse effects of glucose-induced preglomerular vasodilation on glomerular hemodynamics. Glomerulosclerosis is initiated early in the course of diabetic nephropathy by exacerbated expression of cytokines like tumor growth factor β1. Not all type 1 diabetes patients are at risk of nephropathy, probably because some polymorphisms in the various factors involved in its pathogenesis can modulate the course of this disease from one individual to another. Blocking the course of nephropathy by blockers of the renin-angiotensin system relies on solid pathophysiological hypotheses and has proved to be efficacious for improving the prognosis of type 1 diabetes nephropathy.

KEYWORD

Type 1 diabetes - nephropathy - glomerular disease - albuminuria - angiotensin converting enzyme - genetics - transforming growth factors β1

Full Text

References

REFERENCES

1 Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol . 1936; 12 83-97
2 Østerby R, Gundersen H J. Glomerular size and structure in diabetes mellitus 1. Early abnormalities. Diabetologia . 1975; 11 229-239
3 Mauer S M, Steffes M W, Ellis EN Sutherland D ER, Brown D M, Goetz F C. Structural-functional relationship in diabetic nephropathy. J Clin Invest . 1984; 74 1143-1155
4 Lane P H, Steffes M W, Mauer S M. Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion. Diabetes . 1992; 41 581-586
5 Bangstad H J, Østerby R, Dahl-Jorgensen K, Berg K J, Hartmann A, Hanssen K F. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia . 1994; 37 483-490
6 Rudberg S, Østerby R, Bangstad H J, Dahlquist G, Persson B. Effect of angiotensin converting enzyme inhibitor or beta-blocker on glomerular structural changes in young microalbuminuric patients with type I (insulin-dependent) diabetes mellitus. Diabetologia . 1999; 42 589-595
7 Mogensen C E, Christensen C K, Vittinghus E. The stages in diabetic renal disease. Diabetes . 1983; 32 64-78
8 Mogensen C E, Christensen CK Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med . 1984; 311 89-93
9 Viberti G C, Keen H, Wiseman M J. Raised arterial pressure in parents of proteinuric insulin-dependent diabetics. BMJ . 1987; 295 515-517
10 Norgaard K, Feldt-Rasmussen B, Borch-Johnsen K, Saelan H, Deckert T. Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus. Diabetologia . 1990; 33 407-410
11 Mathiesen E R, Ronn B, Jensen T, Storm B, Deckert T. The relationship between blood pressure and urinary albumin excretion in the development of microalbuminuria. Diabetes . 1990; 39 245-249
12 Hansen K W, Mau Pedersen M, Marshall S M, Christiansen J S, Mogensen C E. Circadian variation of blood pressure in patients with diabetic nephropathy. Diabetologia . 1992; 35 1074-1079
13 Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese V M. Microalbuminuria in salt-sensitive patients: a marker for renal and cardiovascular risk factors. Hypertension. 199; 23 195-199
14 Berrut G, Hallab M, Bouhnick B, Chameau A M, Marre M, Fressinaud P h. Value of ambulatory blood pressure monitoring in type I (insulin-dependent) diabetic patients with incipient diabetic nephropathy. Am J Hypertens . 1994; 7 222-227
15 Mogensen C E. Glomerular filtration rate and renal plasma flow in short-term and long-term juvenile diabetes mellitus. Scand J Clin Lab Invest . 1971; 28 91-100
16 Kohner E M, Hamilton A M, Saunders S J, Sutcliffe B A, Bulpitt C J. The retinal blood flow in diabetes. Diabetologia . 1975; 11 27-33
17 Williamson J R, Chang K, Frangos M. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes . 1993; 42 801-813
18 Tooke J E. Microvascular function in human diabetes. A physiological perspective. Diabetes . 1995; 44 721-726
19 Brenner B M. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int . 1983; 23 617-655
20 Parving H H, Hommel E. Prognosis in diabetic nephropathy. BMJ . 1989; 299 230-233
21 Thomsen O F, Andersen A R, Christiansen J S, Deckert T. Renal changes in long-term type 1 (insulin-dependent) diabetic patients with and without clinical nephropathy: a light microscopic, morphometric study of autopsy material. Diabetologia . 1984; 26 361-365
22 Mogensen C E, Chachati A, Christensen C K. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest. 1985-86; 9 85-95
23 Bouhanick B, Berrut G, Chameau A M. Predictive value of testing random urine sample to detect microalbuminuria in diabetic subjects during outpatient visits. Diabete Metab . 1992; 18 54-59
24 Levey A S, Madaio M P, Perrone R D. Laboratory assessment of renal disease: clearance, urinalysis, and renal biopsy. In: Brenner BM, Rector FC Jr, eds. The Kidney. Philadelphia, PA:WB Saunders Co 1991: 919-968
25 Cockfroft D W, Gault M H. Prediction of creatinine clearance from serum creatinine. Nephron . 1976; 16 31-41
26 Krolewski A J, Warram J H, Rand L I, Kahn C R. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med . 1987; 317 1390
27 Rossing P, Rossing K, Jacobsen P, Parving H H. Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes . 1995; 44 739-743
28 Bojestig M, Arnqvist H J, Hermansson G, Karlberg B E, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med . 1994; 30 15-18
29 Kofoed-Enevoldsen A, Borch-Johnsen K, Kreiner S, Nerup J, Deckert T. Declining incidence of persistent proteinuria in type 1 (insulin-dependent) diabetic patients in Denmark. Diabetes . 1987; 36 205-209
30 Seaquist E R, Goetz F C, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med . 1989; 320 1161-1165
31 Borch-Johnsen K, Norgaard K, Hommel E. Is diabetic nephropathy an inherited complication?. Kidney Int . 1992; 41 719-722
32 Quinn M, Angelico M C, Warram J H, Krolewski A S. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia . 1996; 39 940-945
33 Earle K, Walker J, Hill C, Viberti G C. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N Engl J Med . 1992; 326 673-677
34 Pettit D J, Saad M F, Bennett P H, Nelson R G, Knowler W C. Familial predisposition to renal disease in two generations of Pima Indians with 2 (noninsulin-dependent) diabetes mellitus. Diabetologia . 1990; 33 438-443
35 Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin-dependent diabetes. BMJ . 1987; 294 1651-1654
36 Mogensen C E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med . 1984; 310 356-360
37 Kannel W B, Stampfer M J, Castelli W P, Werter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J . 1984; 102 1347-1352
38 Yudkin J S, Forrest R D, Jackson C A. Microalbuminuria as predictor of vascular disease in nondiabetic subjects. Lancet . 1988; 3 530-533
39 Marre M. Microalbuminuria and prevention of renal insufficiency and cardiovascular diseases. Am J Hypertens . 1998; 11 884-886
40 Marre M, Bouhanick B, Berrut G. Microalbuminuria. Curr Opin Nephrol Hypertens . 1994; 3 558-556
41 Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia . 1989; 32 219-226
42 Hostetter T H, Troy J L, Brenner B M. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int . 1981; 19 410-415
43 Scholey J W, Meyer T W. Control of glomerular hypertension by insulin administration in diabetic rats. J Clin Invest . 1989; 83 1384-1389
44 Zatz R, Meyer T W, Rennke H G, Brenner B M. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA . 1985; 82 5963-5967
45 Zatz R, Dunn B R, Meyer T W, Anderson S, Rennke H G, Brenner B M. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest . 1986; 77 1925-1930
46 Anderson S, Rennke H G, Garcia D L, Brenner B M. Short- and long-term effects of antihypertensive therapy in the diabetic rat. Kidney Int . 1989; 36 526-536
47 Nishikawa T, Edelstein D, Liang D u. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature . 2000; 404 787-790
48 Starling E H. Physiological factors involved in the causation of dropsy. Lancet . 1886; 1 1405-1458
49 Ito S, Arima S, Ren Y L, Juncos L A, Carretero O A. Endothelium-derived factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest . 1993; 91 2012-2019
50 Marre M, Leblanc H, Suarez L, Guyenne T T, Menard J, Passa P. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. BMJ . 1987; 294 1448-1452
51 Shankland S J, Ly H, Thai K, Scholey J W. Increased glomerular capillary pressure alters glomerular cytokine expression. Circ Res . 1994; 75 844-853
52 Sharma K, Ziyadeh F N. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-β as a key mediator. Diabetes . 1995; 44 1139-1146
53 Rocco M V, Chen Y, Goldfarb S, Ziyadeh F N. Elevated glucose stimulates TGF-β gene expression and bioactivity in proximal tubules. Kidney Int . 1992; 41 107-114
54 Gilbert R E, Cox A, Wu L L. Expression of transforming growth factor β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of angiotensin converting enzyme inhibition. Diabetes . 1998; 47 414-422
55 Chen S, Iglesias de la Cruz C, Isono M, Ziyadeh F N. Transforming growth factor-β and other cytokines in experimental and human nephropathy. In: Mogensen CE, ed. The Kidney and Hypertension in Diabetes Mellitus. Boston, MA: Kluwer Academic Pub 2000: 313-338
56 Feldt-Rasmussen B, Mathiesen E, Deckert T. Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (insulin-dependent) diabetes mellitus. Diabetologia . 1987; 30 610-617
57 Danser A HJ, van den Dorpel A N, Deinum J. Renin, prorenin and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab . 1989; 68 160-167
58 Jones S, Nyengaard J S. Birth, Barker and Brenner: the concept of low birth weight and renal disease. In: Mogensen, CE, ed. The Kidney and Hypertension in Diabetes Mellitus. 5th ed. Boston, MA: Kluwer Academic Publ 2000: 129-139
59 Hinchliffe S A, Lynch M R, Sargent P H, Howard C V, van Velzn D. The effect of intrauterine growth retardation on the development of renal nephrons. Br J Obstet Gynaecol . 1992; 99 296-301
60 Kasiske B L, O'Donnell M P, Schmitz P G, Kim Y, Keane W F. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int . 1990; 37 880-891
61 Jensen T. Increased plasma level of von Willebrand factor in type 1 (insulin-dependent) diabetic patients with incipient nephropathy. BMJ . 1989; 298 27-28
62 Yip J, Mattock M, Sethi M, Moroccuti A, Viberti G C. Insulin resistance in family members of insulin-dependent diabetic patients with microalbuminuria [letter]. Lancet . 1993; 341 369-370
63 Sharma A M, Jeunemaitre X. The future of genetic association studies in hypertension: improving the signal-to-noise ratio. J Hypertens . 2000; 18 811-814
64 Marre M. Genetics and the prediction of complications in type 1 diabetes. Diabetes Care . 1999; 22 B53-B58
65 Ko B CB, Lam K SL, Wat N MS, Chung S SM. An (A-C)n dinucleotide repeat polymorphic marker at the 5′ end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes . 1995; 44 727-732
66 Heesom A E, Hibberd M L, Millward A, Demaine A G. Polymorphism in the 5′ end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes . 1997; 46 287-291
67 Poirier O, Nicaud V, Vionnet N. Polymorphism screening of four genes encoding advanced glycation end product putative receptors: association study with nephropathy in type 1 diabetic patients. Diabetes . 2001; 50 1214-1218
68 Pociot F, Hansen P M, Karlsen A E, Langdahl B L, Johannesen J, Nerup J. TGF-beta-1 gene mutations in insulin-dependent diabetes mellitus and diabetic nephropathy. J Am Soc Nephrol . 1998; 9 2302-2307
69 Fogarty D G, Harron J C, Hughes A E, Nevin N C, Doherty C C, Maxwell A P. A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM. Diabetes . 1996; 45 1204-1208
70 Marre M, Jeunemaitre X, Gallois Y. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes. J Clin Invest . 1997; 99 1585-1595
71 Doria A, Onuma T, Warram J H, Krolewski A S. Synergistic effect of angiotensin II type 1 receptor genotype and poor glycaemic control on risk of nephropathy in IDDM. Diabetologia . 1997; 40 1293-1299
72 Miller J A, Thai K, Sholey J W. Angiotensin II type 1 receptor gene polymorphism and the response to hyperglycemia in early type 1 diabetes. Diabetes . 2000; 49 1585-1589
73 Staessen J A, Wang J G, Ginocchio G. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular renal risk. J Hypertens . 1997; 15 1579-1592
74 Fujisawa T, Ikegami H, Kawaguchi Y. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia . 1998; 41 47-53
75 Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in angiotensin I conversion enzyme gene accounting for half of the variance of serum enzyme levels. J Clin Invest . 1990; 86 1343-1346
76 Alhenc-Gelas F, Baussant T, Hubert C, Soubrier F, Corvol P. The angiotensin I converting enzyme in the kidney. J Hypertens . 1989; 7 S9-S13
77 Marre M, Bernadet P, Gallois Y. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes . 1994; 43 384-388
78 Hadjadj S, Belloum R, Bouhanick B. Prognostic value of angiotensin-I converting enzyme D/I polymorphism for nephropathy in type 1 diabetes: a prospective study. J Am Soc Nephrol . 2001; 12 541-549
79 Marre M, Bouhanick B, Berrut G. Renal changes on hyperglycemia and angiotensin-converting enzyme in type 1 diabetes. Hypertension . 1999; 33 775-780
80 Rudberg S, Bangstad H J, Rasmussen L M, Østerby R. Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. Diabetes Care . 2000; 23 544-548
81 Pirart J. Diabète et complications dégénératives. Présentation d'une étude prospective portant sur 4400 cas observés entre 1947 et 1973. Diabete Metab . 1977; 3 97-256
82 Mauer S, Steffes M W, Sutherland D ER, Najarian J S, Michael A F, Brown D M. Studies of the rate of regression of the glomerular lesions in diabetic rats treated with pancreatic islet transplantation. Diabetes . 1975; 24 250-255
83 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med . 1993; 329 977-986
84 Feldt-Rasmussen B, Mathiesen E R, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet . 1986; 2 1300-1304
85 Microalbuminuria Collaborative Study Group, United Kingdom. Intensive therapy and progression to clinical albuminuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. BMJ . 1995; 311 973-977
86 Viberti G C, Bilous R W, Makintosh D, Bending J J, Keen H. Long-term correction of hyperglycaemia and progression of renal failure in insulin-dependent diabetes. BMJ . 1983; 286 598-602
87 Daniels B S, Hostetter T H. Aldose reductase inhibition and glomerular abnormalities in diabetic rats. Diabetes . 1989; 38 981-986
88 Soulis-Liparoth T, Cooper M, Papazoglou D, Clarke B, Jerums G R. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes . 1991; 40 1328-1334
89 Walker J D, Bending J J, Dodds R A. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet . 1989; 2 1411-1415
90 Klahr S, Levey A S, Beck G J. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med . 1994; 330 877-884
91 Taguma Y, Kitamoto Y, Futaki G. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med . 1985; 313 1617-1620
92 Marre M, Chatellier G, Leblanc H. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ . 1988; 297 1092-1095
93 Hallab M, Gallois Y, Chatellier G, Rohmer V, Fressinaud P h, Marre M. Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. BMJ . 1993; 306 175-182
94 The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all type 1 diabetic patients with microalbuminuria receive ACE inhibitors?. <~>A meta-regression analysis. Ann Intern Med . 2001; 134 370-379
95 Mogensen C E, Keane W F, Bennett P H. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet . 1995; 346 1080-1084
96 Lewis E J, Hunsiker L G, Bain R P, Rohde R D, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med . 1993; 329 1456-1462
97 Björck S, Mulec H, Johnsen S A, Nyberg G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ . 1992; 304 339-343
98 The Euclid Study Group. Randomized placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet . 1997; 349 1787-1792
99 Mimram A, Insua A, Ribstein J, Bringer J, Monnier L. Comparative effects of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care . 1988; 11 850-853
100 Crepaldi G, Carta Q, Deferrari G, and The Italian Microalbuminuria Study Group in IDDM. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care . 1998; 21 104-110
101 Parving H H, Andersen A H, Shmidt U, Hommel E, Mathiesen E R, Svendsen P A. Antihypertensive treatment postpones end stage renal failure in diabetic nephropathy. BMJ . 1987; 294 1443-1447